Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact

Alicia Galar, Maricela Valerio, Patricia Muñoz, Luis Alcalá, Xandra García-González, Almudena Burillo, María Sanjurjo, Santiago Grau, Emilio Bouza

Research output: Contribution to journalArticleResearchpeer-review

12 Citations (Scopus)

Abstract

© 2017 American Society for Microbiology. All Rights Reserved. Linezolid serum trough (Cmin) and peak (Cmax) levels were determined prospectively in 90 patients. Adequate exposure was defined as a Cmin of 2 to 8 mg/liter. Therapy was empirical (73.3%) or targeted (26.7%). Wide interindividual variability in linezolid Cmin levels was recorded (0.1 to 25.2 μg/ml). Overall, 65.5% of the patients had out-of-range, 41.1% had subtherapeutic, and 24.4% had supratherapeutic trough levels. We did not find a correlation between abnormal levels and adverse events, in-hospital mortality, or overall poor outcome.
Original languageEnglish
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number10
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • Drugs for Gram-positive bacteria
  • Linezolid
  • Therapeutic drug monitoring

Fingerprint

Dive into the research topics of 'Systematic therapeutic drug monitoring for linezolid: Variability and clinical impact'. Together they form a unique fingerprint.

Cite this